Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Forecasted to Post FY2023 Earnings of ($0.90) Per Share

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVSGet Rating) – Equities researchers at Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report issued on Monday, June 6th. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($0.90) per share for the year.

Corvus Pharmaceuticals (NASDAQ:CRVSGet Rating) last issued its earnings results on Thursday, May 5th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.03).

Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 15th. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Corvus Pharmaceuticals in a research note on Friday, March 11th. Finally, StockNews.com assumed coverage on Corvus Pharmaceuticals in a research note on Thursday, March 31st. They set a “sell” rating for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.55.

NASDAQ:CRVS opened at $1.20 on Thursday. Corvus Pharmaceuticals has a 1 year low of $0.94 and a 1 year high of $9.54. The business has a fifty day moving average of $1.30 and a 200-day moving average of $1.88.

In related news, CEO Richard A. Md Miller bought 25,000 shares of Corvus Pharmaceuticals stock in a transaction dated Tuesday, March 15th. The stock was acquired at an average cost of $1.47 per share, with a total value of $36,750.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Leiv Lea bought 35,160 shares of Corvus Pharmaceuticals stock in a transaction dated Wednesday, March 16th. The shares were bought at an average cost of $1.54 per share, with a total value of $54,146.40. The disclosure for this purchase can be found here. Insiders have purchased 86,050 shares of company stock valued at $129,245 in the last ninety days. Company insiders own 45.12% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in CRVS. Millennium Management LLC lifted its holdings in shares of Corvus Pharmaceuticals by 32.6% during the second quarter. Millennium Management LLC now owns 131,435 shares of the company’s stock valued at $351,000 after purchasing an additional 32,339 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Corvus Pharmaceuticals by 10.9% during the third quarter. Geode Capital Management LLC now owns 210,243 shares of the company’s stock valued at $1,017,000 after purchasing an additional 20,702 shares during the last quarter. Zacks Investment Management purchased a new stake in Corvus Pharmaceuticals in the 3rd quarter worth about $48,000. Pura Vida Investments LLC purchased a new stake in Corvus Pharmaceuticals in the 3rd quarter worth about $3,554,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Corvus Pharmaceuticals in the 3rd quarter worth about $97,000. 75.41% of the stock is owned by institutional investors and hedge funds.

About Corvus Pharmaceuticals (Get Rating)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers.

Featured Articles

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.